MA Morgan-Cox

Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

David Isenberg, Michelle Petri, Kenneth Kalunian et al. · Annals of the Rheumatic Diseases · 2015 · 234 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

Joan T. Merrill, Ronald van Vollenhoven, Jill P. Buyon et al. · Annals of the Rheumatic Diseases · 2015 · 224 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Efficacy and safety of mirikizumab ( <scp>LY</scp> 3074828) in the treatment of moderate‐to‐severe plaque psoriasis: results from a randomized phase <scp>II</scp> study

Kristian Reich, Phoebe Rich, Catherine Maari et al. · British Journal of Dermatology · 2019 · 76 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

OP0184 Efficacy and Safety of Tabalumab in Patients with Systemic Lupus Erythematosus (SLE): Results from 2 Phase 3, 52-Week, Multicenter, Randomized, Placebo-Controlled Trials

David Isenberg, Joan T. Merrill, Robert W. Hoffman et al. · Annals of the Rheumatic Diseases · 2015 · 10 citations

Medicine, Pharmacology, Pharmacotherapy +16